CHICAGO / Oct 09, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced the unveiling of Carestation™ 850, its next-generation, FDA 510(k) pendingi anesthesia delivery system that is designed to help care teams adapt to evolving clinical and operational needs. Marking the latest evolution of GE HealthCare’s Carestation portfolio, Carestation 850 has the potential to advance anesthesia care through tools, customizable applications, and a sleek, space conscious footprint. The FDA 510(k) submission for Carestation 850 follows the recent CE mark in Europe and Australian Therapeutic Goods approval in Australia and New Zealand.
Anesthesia professionals today are facing more demands, as health systems grapple with a high volume of increasingly complex surgical cases.ii This strain is faced across the anesthesia field, including anesthesiologists, clinical registered nurse anesthetists and anesthesia assistants. An estimated 68% of anesthesia professionals are at high risk of burnout, contributing to high turnover and staffing shortages across the industry.iii,iv,v These trends are expected to continue, with the anesthesiologist shortage projected to reach 12,500 by 2033, underscoring the need for more efficient care delivery.vi
“In the dynamic operating environment, anesthesia professionals are focused on safety while managing increasingly complex cases and changing patient needs,” said John Beard, MD, anesthesiologist and Chief Medical Officer of Patient Care Solutions at GE HealthCare. “As anesthesia care teams face new challenges, technology can help ease the burden and support safer and more effective care delivery. We’re excited about the potential of Carestation 850 to meet today’s demands in anesthesia delivery and evolve with health systems in the future.”
In surgical and procedural settings, optimizing patient safety is essential, with anesthesia professionals playing a central role in achieving that goal. Carestation 850 is designed to help clinicians more confidently care for each patient and optimize procedural outcomes. To support clinical decision making, the intuitive widescreen display and an enhanced user interface aim to deliver clear data visualization – empowering clinicians to focus on measurements that drive patient care. The system also features a vaporization platform that is designed with advanced alerting capabilities and the ability to refill while in use that could help anesthesia providers proactively manage cases and minimize disruptions. Additionally, Carestation 850 is designed to include tools and applications to aid health systems’ sustainability goals.
“The unveiling of Carestation 850 reinforces our commitment to advancing care that can think one step ahead with its potential to evolve with the changing health systems’ needs through continuously optimized algorithms and adaptable technologies,” said Alla K. Woodson, General Manager, Anesthesia and Global Services, GE HealthCare. “We listened to our customers, and with their help we created Carestation 850, a solution that has potential to transform the future of perioperative care and complement the expertise of clinicians in the operating room by delivering precision, sustainability and efficiency.”
Learn more about Carestation 850 and the full suite of anesthesia solutions at the GE HealthCare booth (#1314) at ANESTHESIOLOGY® 2025 or visit online at gehealthcare.com.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
i | Carestation 850 is 510(k) Pending at FDA. Not Available for Sale in the United States. |
ii | Sg2 Health Care Intelligence. 2024 Impact of Change Forecast Highlights. Vizient Inc. Accessed September 18, 2025. https://vizientinc-delivery.sitecorecontenthub.cloud/api/public/content/47212a11b76244d2b3bc7f0e0db086e5. |
iii | Afonso AM, Cadwell JB, Staffa SJ, Sinskey JL, Vinson AE. U.S. Attending Anesthesiologist Burnout in the Postpandemic Era. Anesthesiology. 2024 Jan 1;140(1):38-51. https://pmc.ncbi.nlm.nih.gov/articles/PMC10751072/. doi: 10.1097/ALN.0000000000004784. PMID: 37930155; PMCID: PMC10751072. |
iv | Berg, Sara. “Physicians in These 10 Specialties Are Less Likely to Quit.” American Medical Association, June 24, 2025. https://www.ama-assn.org/practice-management/physician-health/physicians-these-10-specialties-are-less-likely-quit. |
v | Eydis, Sophie. “Anesthesia Workforce Under Pressure: Shortages, Pay Cuts, Burnout.” Becker’s ASC Review, September 3, 2025. https://www.beckersasc.com/anesthesia/anesthesia-workforce-under-pressure-shortages-pay-cuts-burnout/. |
vi | Eydis, Sophie. “Why Anesthesiologists and CRNAs Are Leaving the Field,” Becker’s ASC Review, August 20, 2025, https://www.beckersasc.com/anesthesia/why-anesthesiologists-and-crnas-are-leaving-the-field/. |
Last Trade: | US$74.17 |
Daily Change: | -0.96 -1.28 |
Daily Volume: | 484,341 |
Market Cap: | US$33.860B |
September 25, 2025 September 10, 2025 August 28, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load